26.06.2018 – 12:45

Metriopharm AG

EQS-News: MetrioPharm AG: MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm

EQS Group-News: MetrioPharm AG / Key word(s): Conference/Study results
MetrioPharm AG: MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at
the 5th WPPAC in Stockholm

26.06.2018 / 12:40

--------------------------------------------------------------------------------
Zurich, June 26, 2018.MetrioPharm AG, a clinical stage pharmaceutical biotech
company developing new medications against chronic immune disorders, today
announced that clinical Phase IIa data obtained from patients with
moderate-to-severe plaque psoriasis will be presented at the 5thWorld Psoriasis
& Psoriatic Arthritis Conference (WPPAC) in Stockholm.

The poster presentation details are as follows:

- Title: The macrophage modulator MP1032 shows safety and efficacy in a human
phase IIa study for the treatment of moderate-to-severe plaque psoriasis

- Poster-ID: 035

- Presented by: Dr. Petra Schulz, Senior Project Manager Drug Development

- Date: 28-30 June 2018

- Location: Stockholm Waterfront Congress Centre, Stockholm, Sweden

Every three years, the International Federation of Psoriasis Associations (IFPA)
organizes the WPPAC, a conference for medical professionals from all over the
world to present their latest developments in psoriasis and psoriatic arthritis
research.

Psoriasis is a chronic-relapsing, inflammatory autoimmune dermatosis, which is
often manifested as plaque psoriasis. A global report published by the world
health organization (WHO) in 2016 describes psoriasis as one of the major health
burdens worldwide and highlights the need for new, tolerable, and effective
medications.

At the WPPAC, MetrioPharm, represented by Dr. Petra Schulz, will present
clinical data of the completed Phase IIa psoriasis study. In this randomized,
double-blind, parallel, and placebo-controlled trial, 46 patients with
moderate-to-severe plaque psoriasis were treated twice daily with 100 mg MP1032.
After only six weeks of treatment, MP1032 reduced the PASI scores by about 28 %
in patients who entered the study with moderate psoriasis. Furthermore, the
excellent safety profile of MP1032 was confirmed in this trial. Dr. Petra Schulz
commented "This makes us look forward to the results of our Phase II study that
is currently running in 14 study centers over Germany as well as Poland and is
expected to be finalized in the first quarter of 2019."

About MP1032

MP1032 is the lead compound of a class of proprietary immune modulators
developed by MetrioPharm. MP1032 is believed to modulate the oxidative
stress-mediated activation state of macrophages and downregulate the M1 state.
In contrast to other immune-modulating and diseasemodifying drugs, MP1032 does
not impact T-cells and preferentially affects macrophages at the sites of
inflammation. MP1032 has shown anti-inflammatory activity in animal models of
disease and a favorable toxicology profile in pre-clinical studies.

About MetrioPharm

MetrioPharm AG is a pharmaceutical biotech company developing drug compounds for
the treatment of autoimmune and other inflammatory diseases. MetrioPharm's
MP1000 pipeline consists of small molecule immune modulators for unmet medical
needs in Immune-Mediated Inflammatory Diseases (IMIDs). MetrioPharm AG was
founded in 2007 and is headquartered in Zurich with research facilities in
Berlin.

Forward-looking statements

This press release contains forward-looking statements that involve risks and
uncertainties and are consistent with MetrioPharm's assessment as of the date of
this release. Such forwardlooking statements are neither promises nor
guarantees, but are subject to numerous risks and uncertainties, many of which
are beyond MetrioPharm's control, that could cause actual results to differ
materially from those contemplated in these forward-looking statements.
MetrioPharm does not assume any obligation to update forward-looking statements
with respect to changed expectations or new events, conditions or circumstances
on which these statements are based. A liability or guarantee and, if
applicable, claims for topicality, correctness and completeness of these data
and information are excluded and cannot be derived either explicitly or
impliedly.



Contact:
Eva Brysch
Head of Investor Relations & Corporate Communications
....................
MetrioPharm AG
Bleicherweg 45
CH-8002 Zürich

MetrioPharm Deutschland GmbH
Am Borsigturm 100
D-13507 Berlin

T +49 (0) 30 33 84 395 40
F +49 (0) 30 33 84 395 99

E  invest@metriopharm.com
W www.metriopharm.com-----------------------------------------------------------
---------------------Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=UUJFOJESTX
Document title: MetrioPharm Press Release WPPAC Conference June 26, 2018
26.06.2018

--------------------------------------------------------------------------------
End of Corporate News
--------------------------------------------------------------------------------

Language: English

Company:  MetrioPharm AG

          Bleicherweg 45

          8002 Zurich

          Switzerland

Phone:    +41 (44) 515 21 97

Fax:      +41 (44) 201 74 75

E-mail:    info@metriopharm.com

Internet: www.metriopharm.com

ISIN:     CH0107076744

Valor:    A0YD9Q



 

End of News EQS Group News Service

--------------------------------------------------------------------------------

698769  26.06.2018